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Abstract 
 
Background: Nailfold capillaroscopy (NC) is an important diagnostic tool in systemic sclerosis 
(SSc). Confirmation of NC as a prognostic factor could facilitate earlier intervention and slow 
disease progression in SSc. We undertook a systematic literature review to evaluate the 
prognostic value of NC in predicting SSc disease progression  
Methods: Standardised searches of EMBASE and MEDLINE were undertaken to identify 
longitudinal studies of adult subjects with SSc reporting the prognostic value of NC for any 
aspect of disease progression and/or survival. Non-English, non-original research, animal 
studies, non-adult studies and non-full length reports were excluded from the analysis 
(PROSPERO 2017:CRD42017071719). Wide heterogeneity in study design, prognostic factor 
measurement and study outcomes necessitated a qualitative data synthesis. The “QUality In 
Prognosis Studies” (QUIPS) risk-of-bias tool was used to assess study quality. Study selection, 
data extraction and risk-of-bias assessment were each undertaken independently by 2 
reviewers and consensus reached where necessary. 
Results. Of 942 retrieved articles, 18 studies fulfilled the inclusion criteria. The majority of 
studies (16/18, 89%) reported positive associations between baseline NC appearances (using 
a variety of qualitative, semi-quantitative and quantitative NC endpoints) and clinical 
outcomes including digital ulcer (DU) occurrence/healing, survival, disease progression (using 
domains of Medsger disease severity scale), calcinosis, skin progression, pulmonary arterial 
hypertension (PAH), and/or a composite analysis of “cardiovascular events”. Application of 
the QUIPS tool identified a moderate-high risk of potential bias in 6/18 studies for study 
participation, 3/18 studies for study attrition, 10/18 for prognostic factor measurement, 5/18 
for outcome measurement, 13/18 for confounders and 13/18 for statistical analyses. Study 
quality limited the strength of the conclusions drawn from these studies. The most important 
source of potential bias across the studies was insufficient adjustment for potential 
confounders; such as existing DU disease in studies evaluating future DU occurrence. Recent 
work suggests NC evolution is an important predictor of disease progression in SSc. 
Conclusions: High levels of potential bias relating to study confounding and statistical analysis 
make it difficult to draw conclusions regarding the prognostic role of NC in SSc. There is strong 
evidence supporting an association between NC abnormalities (particularly capillary loss) and 
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disease severity (particularly vascular manifestations such as DU, calcinosis and PAH). 
Evolution of NC appearances may represent a more important predictor of disease 
progression which could have important implications for the future use of NC in the routine 
longitudinal assessment and management of SSc. 
 
Keywords: Systemic Sclerosis, Scleroderma, Nailfold capillaroscopy, Prognosis, Clinical 
phenotype, Biomarkers, Systematic Literature Review 
 
Abbreviations 
Digital ulcers (DU) 
International prospective register of systematic reviews (PROSPERO) 
Nailfold capillaroscopy (NC) 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Pulmonary Arterial Hypertension (PAH) 
Systemic sclerosis (SSc) 
 
Funding:  This research did not receive any specific grant from funding agencies in the 
public, commercial, or not-for-profit sectors. Ms Dolcie Paxton undertook this work as part 
of a University of Bristol Medical School 3rd year Student Selected Components (SSC) 
placement. 
 
Conflicts of Interest: None of the authors report any conflicts of interest relevant to the 
content of this work  
Prognostic Value of NC in SSc  4 
Introduction 
Systemic sclerosis (SSc) is a rare multisystem connective tissue disease characterised by a 
autoimmunity, aberrant tissue remodelling and vasculopathy [1]. The nailfold provides an 
opportunity to directly visualise the evolving obliterative microangiopathy of SSc and the 
characteristic nailfold capillary abnormalities have been well-described [2]. The 
morphological appearance of nailfold capillaries do not remain static and longitudinal studies 
have charted the progression of capillary abnormalities over time [3, 4]. The terminology used 
to classify nailfold capillary abnormalities reflect distinct patterns visualised at different 
stages of the disease with “early” changes characterised by the presence of few giant 
capillaries with few microhaemorrhages and “late” changes characterised by progressive 
capillary loss and disorganised neovascularisation [5] (Figure 1).  
 
The diagnostic value of nailfold capillaroscopy (NC) in SSc [2, 6] has led to its inclusion in 
recent classification criteria for SSc [7, 8]. NC has also been shown to have an important 
predictive role identifying patients with Raynaud’s phenomenon at risk of progression to 
overt SSc-spectrum disorders [9-11]. Another early observation was an association between 
severe NC abnormalities and internal organ involvement in SSc [12, 13]. Subsequent studies 
have identified associations between NC changes and a number of clinical features including 
cardiopulmonary disease [14], digital ulcers (DU) [15], calcinosis cutis [16], telangiectases 
[17], acro-osteolysis [16] and others [18]. A number of cross-sectional studies reporting 
associations between NC appearances and clinical phenotype have speculated about the 
prognostic and/or predictive value of NC in SSc but lacked longitudinal assessments to 
confirm this [14, 15, 18, 19].   
 
Prognostic studies seek to predict future outcomes in individuals based on clinical and non-
clinical factors [20]. Prognostic factors can offer insight into disease pathogenesis and support 
medical decision making [21]. If a prognostic role for NC were confirmed, it could be used to 
guide early intervention to modify the disease course of SSc [22]. We report the findings of a 
systematic literature review designed to evaluate the prognostic value of NC in predicting 
disease-specific outcomes in longitudinal studies of SSc. 
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Methods and analysis 
 
Protocol development and review registration 
A study protocol was developed according to PRISMA-P guidelines [23] and registered in the 
International Prospective Register of Systematic Reviews (Registration: PROSPERO 
2017:CRD42017071719).  
 
Eligibility criteria 
Studies reporting the relationship between NC and disease progression, prognosis and/or the 
presence/emergence of specific clinical features of systemic sclerosis were included in this 
systematic literature review. Applying the PICOS framework, we sought to evaluate 
publications that fulfilled the following study characteristics: 
 
Population: Adults (18 years or older) with a diagnosis of systemic sclerosis. 
 
Intervention: Studies reporting the use of NC as a prognostic factor. All methods of image 
acquisition and analysis were eligible for inclusion.  
 
Comparisons: None 
 
Outcomes: All relevant SSc-specific or SSc-associated outcomes including, but not limited to, 
organ-specific complications of SSc (e.g. digital ulcers, pulmonary arterial hypertension, 
scleroderma renal crisis etc.), clinical phenotype (e.g. SSc disease subsets), patient 
demographics (e.g. disease duration, gender, age), survival, health-related quality of life, 
functional status and other co-morbidities (e.g. concomitant cardiovascular disease).  
 
Study design:  Only longitudinal studies that reported outcomes at a time-point distinct from 
the baseline NC assessment (i.e. appropriate design to examine prognostic value) were 
eligible for data synthesis. Eligible study types included cohort studies (prospective or 
retrospective) and observational studies. The following studies were excluded from the 
analysis; animal studies, non-English language publications, studies of childhood/juvenile SSc, 
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studies of mixed patient populations (e.g. primary Raynaud’s phenomenon, undifferentiated 
connective tissue diseases or overlap syndromes) in which a SSc cohort was not adequately 
reported, studies designed to develop/validate measurement scales, studies investigating the 
effectiveness of NC as a diagnostic/screening test, randomized controlled trials, case reports, 
qualitative research, non-original research publications (i.e., editorials, reviews), abbreviated 
reports (e.g. letters to editors) and conference proceedings. 
 
Information sources and search criteria 
Electronic searches were undertaken in Medline and EMBASE databases. The search criteria 
were developed in accordance with recommendations governing systematic reviews of 
evaluations of prognostic variables [24]. No publication date or language restrictions were 
applied to the searches. Full details of the specific search criteria applied within each database 
are available as supplementary material (Supplementary material 1). 
 
Study selection  
All titles and abstracts generated by the search were screened independently by two review 
authors (JP and DP) for relevance and eligibility of studies for full text review. Cohen’s Kappa 
statistics were used to assess agreement between reviewers. Any discrepancies in agreement 
were reviewed together, with resolution through discussion, at each step of the study 
selection process. A grey search of potentially relevant cited articles identified during full text 
review was undertaken.  
 
Data extraction and synthesis from selected studies 
Data was independently extracted by both reviewers (JDP and DP) using a standardized form 
piloted during protocol development. The data extraction form collated relevant study details 
including date of publication, publication source, country of origin, study design, initial 
population of the study, study attrition, inclusion criteria, exclusion criteria, NC method, NC 
analysis, blinding of NC assessor, disease outcomes assessed (e.g. organ-specific 
manifestations of SSc), approach to statistical analysis and a summary of key findings. A 
qualitative data synthesis of the study findings was planned due to an anticipated high study 
heterogeneity in terms of study design, NC image acquisition/analysis and outcomes 
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rendering any meaningful attempt at meta-analysis inappropriate. There was an intention to 
contact corresponding authors where clarification was deemed necessary.  
 
Risk of Bias Assessment 
The quality of prognostic studies (and risk of bias) was independently assessed by 2 reviewers 
(JP and DP) using the QUality in Prognosis Studies (QUIPS) tool [25, 26] with discrepancies in 
agreement resolved through discussion where necessary (see Supplementary material 2 for 
further details). 
 
Results 
 
Study selection 
Simultaneous searches in EMBASE (n=610) and Medline (n=332) were conducted on 12th July 
2017 identifying a total of 942 articles. After removal of duplicate results (n=223), 719 articles 
were screened for eligibility in an initial title and abstract review resulting in the identification 
of 23 articles that proceeded to full text review. There was good agreement between 
reviewers at title and abstract screening with an unweighted Cohen’s Kappa of 0.7 (see 
supplementary material 3 for details) with discordance in only 15/719 abstracts that was 
easily resolved through discussion, without the need for independent arbitration. Full text 
review of 23 manuscripts, led to further exclusion of 6 studies and the identification of 1 study 
deemed eligible for inclusion during “grey search” review of cited papers. This resulted in the 
identification of 18 papers that proceeded to full data extraction. The full study selection 
process is summarised in Figure 2. A summary of the main study attributes, study design and 
reported findings is presented in Table 1. 
 
Geographical participation and publication date   
The majority of the studies were undertaken in Europe (14/18, 78%) [27-40]; over half of 
which originated from 3 research teams. The remaining studies were led by centres in Canada 
[41, 42], Australia [43] and Brazil [44]. No prognostic studies of NC to date have been 
supported by US investigators. This is a developing field with the majority of studies published 
between 2013 and 2017 (10/18, 56%) with only 2 studies preceding 2009 [35, 42]. 
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Study characteristics 
The majority of studies were prospective longitudinal studies (13/18, 72%) with relatively 
short follow up. The duration of follow up in the prospective studies varied substantially 
according to the disease outcome of interest with 5 studies (38%) assessing outcomes within 
6 months (all examining relationship between NC and DU occurrence/healing) [29-33], with 
the longest reported prospective follow up of 27 months (± 18 months) adopted in a study 
examining cardiovascular outcomes [39]. The follow up period reported in the retrospective 
studies was longer still (up to 20 years), particularly in the studies examining independent risk 
factors for survival [35, 42-44]. 
 
Study populations 
A total of 3,385 SSc patients have been evaluated longitudinally in prognostic studies of NC. 
Multi-centre studies included the largest number of patients (total 2,445, with average of 272 
per study) whereas total recruitment to single centre studies was lower (940 patients in 9 
studies averaging 104 per study). The patients were recruited according to criteria used at the 
time of enrolment which included the 1980 preliminary ARA classification criteria [45] 
(applied in most studies whose publication pre-dated 2015), the LeRoy and Medsger 
classification criteria for early SSc [7] and latterly the 2013 ACR/EULAR classification criteria 
for SSc [8]. Some studies relied upon a clinician diagnosis of SSc [35, 38-42]. Most studies can 
be considered a representative SSc patient cohort and the QUIPS risk-of-bias assessment was 
considered “low” for the majority of studies (12/18, 66%, Table 2). Other studies incorporated 
eligibility criteria (e.g. the presence of specific NC abnormalities at baseline [30-33]) or a priori 
patient grouping to enrich populations with patients at a high risk of developing the outcome 
of interest [29] that limited the generalisability of the study findings. Other studies examined 
disease outcomes that necessitated a particular baseline clinical phenotype (e.g. the need for 
baseline DU when examining the relationship between NC abnormalities and DU healing [27]) 
or required the active exclusion of patients with relevant phenotype e.g. pre-existing 
cardiovascular risk factors [34, 39, 40]. Study attrition was generally reported to be low. Some 
studies did not report attrition despite the recruitment of large numbers of patients (e.g. 
n=219 in [30]) and/or a protracted follow-up period (e.g. 3 years in [34]). The QUIPS risk-of-
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bias assessment was only considered “high” in a single study in which >1/3 of patients were 
lost to follow-up increasing the potential for selection bias [44]. 
 
Prognostic factor measurement 
NC was one of several exploratory prognostic factors in each of the retrospective longitudinal 
studies [35, 41-43]. For the majority of prospective studies, NC was the principle or only PF 
measured although in others NC was one of a larger repertoire of exploratory PFs [39, 40]. NC 
image acquisition and analysis varied across studies. Where uniformity in approach existed, 
it was typically the result of studies arising from the same research group e.g. [30-33]. Most 
studies provided sufficient description of NC image acquisition and analysis but in others 
important details were missing [34, 35, 41], raising concerns as to whether NC had been 
measured using a standardised approach for all participants. The majority of studies reported 
NC assessment of all of 8 fingers with one study including the thumbs [44] whereas another 
restricted assessment to a single digit [43]. Various methods of NC image acquisition have 
been used at image magnifications ranging from 18x to 200x magnification (Table 1). One 
multicentre study used dermatoscopes rather than formal videocapillaroscopy to acquire NC 
images [41].  Seven studies reported blinding of the NC assessor (Table 1) although the extent 
to which PF assessment was entirely free of bias might be questioned. For example, the choice 
of “the most representative images” (one per finger) applied in some studies could be 
influenced by the presence of active DU or digital pitting at the time of the NC assessment.   
 
A variety of qualitative, semi-quantitative and quantitative approaches to NC image analysis 
(sometimes in combination) have been applied in prognostic studies of NC and are 
summarised in Table 1. Commonly used methods include the qualitative NC classification 
approach initially proposed by Cutolo et al. [5] which was included in 7/18 (39%) of studies 
from a variety of centres, and the Capillaroscopic Skin Ulcer Risk Index (CSURI) used in 4 
studies (22%, all originating from the same group [30-33]). Across all studies, the bias rating 
for PF measurement using the QUIPS tool was considered “moderate” for 9/18 (50%) of the 
studies and “high” for 1 study which failed to report the method of NC image acquisition 
(Table 2). More recent prospective studies have reported a standardised approach to NC 
Prognostic Value of NC in SSc  10 
image acquisition and analysis that would be more easily reproducible and less amenable to 
bias [28, 29]. 
 
Outcome measurement 
The studies reported associations between baseline NC appearances (using a variety of 
qualitative, semi-quantitative and quantitative NC endpoints) and clinical outcomes including 
digital ulcer (DU) occurrence/healing [26, 28-33, 35], survival [34, 41-43], disease severity 
progression (including peripheral vascular using domains of disease severity scale [DSS]) [27, 
36, 37], calcinosis [40], skin progression [27], pulmonary arterial hypertension [27, 39], and/or 
composite analysis of “cardiovascular events” [38]. Outcome measure assessments generally 
conformed to accepted definitions/validated instruments although some studies did not 
provide detailed descriptions of relevant clinical variable definitions (e.g. what constitutes the 
presence/healing of DU). The approach to outcome measure assessment was generally 
unbiased and rated “low” for most studies (13/18, 72%) using the QUIPS tool. There were 
examples in which the assessment of the clinical outcome (e.g. whether there had been the 
occurrence of new DU and/or healing of existing DU) could have been influenced by the 
baseline NC findings (Table 2). 
 
Reported prognostic associations of NC in SSc 
The majority of studies (17/18, 94%) reported at least 1 positive association between NC 
findings and clinical outcomes raising the possibility of reporting bias (Table 1). Across all of 
the studies, it was nailfold capillary loss (a feature considered to represent “late” disease and 
often classified as such) assessed using a variety of quantitative, semi-quantitative and 
qualitative approaches that was most often reported as being a predictor of a broad range of 
future SSc outcomes ranging from DU healing [27, 33], new DU occurrence [29-34], 
progression of peripheral vascular disease severity according to the DSS [36-38], progression 
of lung disease severity according to DSS [37], mortality [43, 44], cardiovascular events [39], 
pulmonary arterial hypertension [PAH] [40] and calcinosis [41]. Interpretation of previous 
studies is limited by moderate-to-high risk of bias across each of the domains of the QUIPS 
tool making it difficult to draw strong conclusions regarding the prognostic value of NC in SSc. 
A “high” risk-of-bias rating for at least 1 of the QUIPS domains was present in 12/18 (67%) 
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studies. The main issues with study quality were related to confounding and statistical 
analysis with 12/18 (67%) of studies rated as “high” across one or both of these domains (see 
Table 2 and the more detailed discussion that follows this section).  
  
The most recently published study examining the prognostic role of NC in SSc is notable for 
the quality of the study design (and was the only study rated “low” risk-of-bias across all 
domains of QUIPS)  and for the fact that it challenges the findings of earlier work [28]. This 
study reported an independent association between the presence of neoangiogenesis 
(another feature of “late” disease) on baseline NC and future lung vascular progression [28]. 
Baseline capillary drop out was not an independent risk factor for disease progression on 
multivariate analysis but there were novel associations between NC evolution (assessed 
annually for 3 years) and disease progression with progressive capillary loss being associated 
with a broad range of worsening disease outcomes (Table 1) [28]. An increased number of 
giant capillaries, meanwhile, appears to confer a protective effect against new DU and overall 
disease progression suggesting effective vascular remodelling can occur in SSc [28]. 
 
Study confounding 
There was a high likelihood that the observed effect of NC on the outcome of interest could 
have been distorted by other factors related to both NC and outcome in many of the reported 
studies. Overall, 11/18 (61%) studies were rated as “high” risk of bias due to inadequate 
accounting for potential confounders (Table 2). For example, some studies did not supply 
baseline clinical data to confirm whether the clinical phenotype had evolved during the 
intervening period between NC and outcome assessment [37]. Inadequate adjustment for 
confounding might explain conflicting accounts as to whether NC abnormalities are a risk 
factor for mortality [35, 42-44]. Kayser et al. reported high avascular scores on NC as an 
independent predictor of mortality in a study that included 12 deaths, 4 of which were 
attributable to pulmonary arterial hypertension (PAH) [44]. At the time of NC assessment, 4 
patients had echocardiographic evidence of PAH (with differences in the proportion with PAH 
at baseline in the “deceased” cohort versus the “alive” cohort approaching statistical 
significance [36% vs. 13%, p=0.07]) [44]. The presence of PAH, however, was excluded from 
the multivariate cox proportional hazards model reported to demonstrate the association 
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between the avascular score and mortality [44]. Similarly, Hissaria et al. reported a significant 
hazard regression ratio of 1.60 (95%CI 1.06-2.42) for mortality using categorical NC patterns 
treated as 0-3 continuous variables (grade 3 indicative of capillary drop out) but it was unclear 
whether this analysis was adjusted for the presence of diffuse scleroderma, interstitial lung 
disease (ILD) and the presence of anti-Scl-70 autoantibodies; each of which had been found 
to be independently associated with both capillary drop out and mortality in separate 
analyses reported in the study [43]. Similarly, studies reporting a predictive role of NC 
abnormalities in predicting future cardiovascular events and PAH did not incorporate 
important potential confounders (such as baseline echocardiographic parameters and serum 
brain natriuretic protein) in multivariate logistic regression analyses despite observed 
baseline differences in these variables between patients with/without future cardiovascular 
events/PAH [39, 40].  
 
Inadequate accounting for confounders may have influenced  studies reporting the 
prognostic value of NC in predicting future DU occurrence (e.g. [30-34, 36]). A recent well-
designed study (considered low risk of bias for study confounding) examining the association 
between NC abnormalities and future DU identifiedclinical features such as the presence and 
number of active DU at baseline as the strongest predictors of new DU occurrence; although 
capillary drop out was an independent predictor of new DU within the cohort of patients with 
a history of DU [29]. 
 
The impact of adequately adjusting for potential confounders is highlighted by the findings of 
the aforementioned recent prospective study whose findings conflict with previous studies 
examining similar outcomes [28]. Univariate analysis identified severe loss of capillaries at 
baseline NC as a predictor of overall disease progression, the occurrence of new DU, lung 
vascular progression, skin progression and worsening of the DSS, however, none of these 
associations persisted on multivariate analysis [28]. In contrast, neoangiogenesis at baseline 
NC retained a significant association with the lung vascular progression (HR 11.12, 95%CI 
1.19-103.79, p=0.036) with a strong trend for overall disease progression (HR 2.77, 95% CI 
0.89-8.56) on multivariate analysis that controlled for relevant confounders [28]. 
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Statistical analysis and reporting 
A number of studies applied analytical methods that limit interpretation of the study findings. 
For example, the use of Mann Whitney U to compare the distribution of quantitative NC 
findings at baseline between patients whose DUs healed versus those whose DUs persisted 
(capillary density 4.9 vs. 3.3, p=0.05) supports an association between baseline NC changes 
and DU healing but is unable to examine the independent prognostic value of NC [27]. 
Similarly, a number of studies have applied receiver operating curve characteristics to confirm 
an association between baseline NC abnormalities and future digital ischaemic outcomes [31-
33, 36]. This approach does not allow for adjustment for important baseline confounders 
(such as the presence of DU at baseline) and therefore limits the conclusions drawn 
concerning the independent prognostic value of NC. Once again, adjustment for confounding 
is paramount and multivariate cox proportional hazards regression modelling provides an 
opportunity to achieve this; although this approach is not beyond reproach if relevant 
confounding factors are not incorporated into the model (as highlighted previously [43]). 
Moreover, regression analysis models struggle to manage situations in which a confounding 
factor (such as history of DU) completely separates a predictor variable (such as NC features) 
for a given outcome (new DU occurrence). The statistical phenomena of quasi-separation may 
explain the exceptionally high odds ratio and broad confidence intervals (OR 99.95, 95%CI 
20.03-498.86) obtained following multivariate analysis in the study examining the prognostic 
value of the CSURI in predicting new DU [30, 46]. The strength of the association between NC 
abnormalities and future DU was certainly considerably greater than in subsequent larger 
longer-term multicentre initiatives [29]. A propensity for smaller studies of single prognostic 
marker studies to sometimes report higher relative risks than larger studies has been noted 
previously [47]. Overall, 13/18 (72%) of studies were rated as moderate/high risk of bias 
related to analysis or reporting.  
 
Discussion 
 
To our knowledge, this is the first study to systematically review and critically appraise studies 
reporting the prognostic value of NC in SSc. This is a rapidly developing field with almost half 
of all prognostic studies published within the last 3 years.  We identified 18 studies examining 
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the prognostic value of NC in SSc; the majority of which reported a prognostic role for NC 
abnormalities in predicting a broad range of disease-related outcomes, including mortality. 
Issues with study quality (relating primarily to study confounding and statistical analysis) 
limits the strength of conclusions that can be drawn from many of the studies reviewed and 
the evidence confirming a prognostic role for single time-point NC assessments in predicting 
disease outcomes in SSc at the present time is limited. Many of the studies identified in this 
review were early exploratory studies that would be termed “Phase I” prognostic factor 
studies which are known to be vulnerable to type one (false positive) errors [21]. Common to 
observations in other fields of prognostic study research [48], many of the identified studies 
focused on the importance of NC (a relatively high-cost biomarker), whilst over-looking the 
potential relative value of basic clinical assessments (such as history/presence of active DU); 
potentially over-estimating the added value gained from NC in predicting future SSc 
outcomes. A number of studies examined multiple prognostic factors and outcomes raising 
the potential for selective reporting bias in studies lacking a robust a priori statistical analysis 
plan [48]. Similar issues have been noted during efforts to synthesise evidence from 
prognostic studies in other disease areas [47]. Standards for the design, analysis and reporting 
of prognostic studies have been proposed that could support future data synthesis efforts in 
this field [21, 47-50].  
 
The studies identified in this review do contribute to a larger body of evidence from cross-
sectional studies identifying strong associations between NC abnormalities (namely capillary 
drop out) and a broad range of disease-related outcomes, particularly concerning vascular 
features such as DU disease and PAH [12-19].  Whilst the association between NC 
abnormalities and clinical features sheds important light on the pathophysiology of SSc, it 
does little to support treatment decisions in clinical practice (and it is possible such NC 
abnormalities develop after the outcome of interest). Confirming a prognostic value of NC 
could therefore facilitate earlier intervention and support improved outcomes. The recent 
work by Avouac et al. [28] is of major importance in this regard for 3 reasons. Firstly, the 
design, conduct, analysis and reporting of this large prospective observational cohort study 
were largely free of the aforementioned biases that can influence the interpretation of 
prognostic studies (it was the only study to be rated “low” across all of the domains of the 
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QUIPS tool). Secondly, the strength of the prognostic value of baseline NC was weaker than 
in other studies and only partially confirmed after multivariate Cox analysis. Thirdly, this study 
identified an important relationship between the evolution of NC abnormalities and future 
disease progression in SSc. Of particular interest were changes in NC appearances that 
appeared protective (increased number of giant capillaries) against SSc outcomes, whereas 
increased capillary loss portended worse outcomes across a broad range of clinical outcomes. 
These findings, if replicated, have important ramifications for the routine assessment of SSc 
and strengthens the case for serial NC to be incorporated into routine clinical monitoring of 
SSc disease progression.   
 
This work has identified a number of factors that should be considered for future prognostic 
studies of NC in SSc. Common to many human diseases, the disease progression in SSc is likely 
influenced by patient demographics, clinical phenotype, and a complex interplay of a wide 
range of serological, genetic, environmental, treatment and psychosocial factors. As such, a 
multi-variable approach to the design and analysis of future prognostic studies of SSc is 
essential if we are to confirm a specific role for NC in the routine monitoring of SSc [20]. 
Ensuring sufficient observer blinding during measurement of the both NC (or other prognostic 
factor) and outcomes is another important aspect to consider in future prospective cohort 
prognostic studies [20]. It has been suggested that prognostic research of complex disease 
requires several hundred outcome events to avoid overestimations of the predictive 
performance of the model [20]. It has also been suggested that the analysis and reporting of 
prognostic studies “should focus on absolute risk estimates of outcomes given combinations 
of predictor values” [20].  Regression modelling with stepwise variable selection (e.g. Cox 
proportional hazards regression model that was used in many of the identified studies) 
sometimes performs badly in validation cohorts and cannot be confidently applied unless 
outcome events are several fold higher than the number of potential prognostic variables 
studied [21]. Moreover, use of the same data to develop the model and estimate regression 
coefficients can lead to biased estimates whose statistical significance can be misleading [21]. 
Such issues surrounding sample size present a particular problem for prognostic research in 
rare diseases such as SSc. 
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There were a number of limitations to the present work. The exclusion of unpublished studies 
(e.g. conference abstracts) and abbreviated reports from this review increases the risk of 
publication and reporting bias and may have contributed to the high number of positive 
studies. We took this decision to ensure we had sufficient information available to fully assess 
each of the studies subject to full data extraction. We did identify one example of a letter to 
editor [51] reporting the abridged findings of a longitudinal study examining the prognostic 
value of NC in SSc that was not eligible for inclusion in our study analysis due to our study 
eligibility criteria. In contrast to clinical trials and systematic literature reviews, there is 
currently no agreed standard for registering prognostic study protocols to facilitate easier 
identification of unpublished work. Relatively small positive studies (many undertaken 
without peer-reviewed funding) have a tendency to bias the literature of prognostic research 
[48]. We don’t believe this has biased our principal conclusions as our critical appraisal of the 
quality of published studies has led us to caution against over-estimating the prognostic value 
of NC in SSc. We have raised a number of methodological issues that should be considered in 
the design of future prognostic studies in this field.   
 
Conclusions 
 
The quality of many of the previous prognostic studies of NC in SSc have limited the 
conclusions that can be drawn from such work.  More recent high-quality studies have 
reported findings which could have major implications for the positioning of NC in the 
longitudinal assessment and management of SSc in the future. 
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Tables and Figures 
 
Figure 1. Examples of capillary appearances at the nailfold of a healthy control and in 
systemic sclerosis 
 
A) Appearances at 50x magnification in a healthy control demonstrating uniformly-spaced nailfold capillaries of similar 
size and length. The distal row typically has a capillary density of >10 capillaries per mm (1mm size bar presented for 
interpretation); B) Appearances at 200x magnification of the “early” changes of systemic sclerosis [5] demonstrating few 
giant capillaries (no haemorrhages visible in this image) ; C) Appearances at 200x magnification of the “active” changes 
of systemic sclerosis [5] demonstrating the presence of giant capillaries, some reduction in capillary density and the 
remnants of a microhaemorrhage within the cuticle; D) The characteristic appearances at 200x magnification of the 
“late” changes of systemic sclerosis [5] demonstrating significant capillary loss and extensive disorganised 
neoangiogenesis. 
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Figure 2. Study selection flow diagram presented according to PRISMA statement 
NC, nailfold capillaroscopy 
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Table 1. Summary table of study characteristics and major findings of studies examining the prognostic value of nailfold capillaroscopy in systemic sclerosis 
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Author 
& Date  
Origin Desi
gn 
Description Study 
Population 
Attrition Classification 
Criteria for SSc 
Exclusion 
Criteria 
NC Method NC Analysis Assessor 
blinding 
Disease 
outcome(s)  
Statistical methods to investigate 
relationship between PF and outcome 
Summary of key reported findings and additional comments 
Scussel-
Lonzetti 
et al. 
2002 
[42] 
Canada R L Risk factors for 
mortality in SSc 
309 SSc pts 
(1st seen 
1984 to 
1999) 
NC only 
available 
for 294 
Clinician 
diagnosis of SSc 
Nil All digits of 
both hands. 
8-50X magn.  
Categorical analysis of: 
(i) Cap dilatation (0-4 
scoring)  
(ii) Avascular areas 
(scored A-D). 
Yes Mortality 
(census 
2000) 
Univariate Cox proportional hazards 
regression analysis followed by multivariate 
analysis using stepwise Cox regression 
analysis examining multiple variables of 
interest (including NC). 
66 patients died during follow-up. Capillary loss and capillary dilatations 
at baseline assessment not independent risk factors for mortality. Follow-
up period for each patient at time of mortality assessment not presented 
(disease duration varied from <1 year to 17.5 years). Unclear whether 
potential confounding effect of disease duration included in analysis. 
Simeón 
et al. 
2003 
[35] 
Spain R L Risk factors for 
mortality in SSc  
79 SSc pts 
(1st seen 
1976 to 
1996) 
NC only 
available 
for 69 
Clinician 
diagnosis SSc 
and disease 
duration <15 
yrs; 65/79 
fulfilled 1980 
ARA criteria 
Nil  2nd-5th digits 
of both 
hands 
(magn. not 
reported) 
Qual assessment of cap 
appearances into 
“active” (predominance 
of cap loss) and “slow” 
(megacapillaries and no 
cap loss) 
Not 
reported 
Mortality Mortality rate expressed as person-years. 
The log-likelihood ratio x2 test was used as 
part of a crude analysis examining factors 
associated with survival. The Cox 
proportional hazards model was used to 
identify independent prognostic factors 
(including NC). 
There were 12 deaths (11 of SSc-organ complications and 1 of cancer). On 
crude analysis, lung involvement (FVC <70%), PAH, SSc renal crisis, an 
“active” capillaroscopic pattern (p=0.02), pericardial effusion and age 
>60yrs at diagnosis were associated with shorter survival. On multivariate 
analysis, only age >60yrs at diagnosis, FVC <70% and SSc renal crisis were 
independent prognostic factors suggesting the initial observed effect of 
NC on survival on crude analysis distorted by confounders.    
Alivernin
i et al. 
2009 
[27] 
Italy P L Prognostic 
factors related 
to DU healing 
at 20 months.   
130 in initial 
study (34 
baseline DU 
eligible for 
longitudinal 
analysis) 
4 with 
baseline 
DU not 
included 
in 
analysis.  
1980  ARA 
classification 
criteria for SSc 
Nil  Not 
reported 
Quant analysis of mean 
value of megacapillaries 
and cap density. Qual 
analysis of avascular 
areas, micro-
haemorrhages & cap 
morphology.  
Not 
reported 
DU healing 
in pts with 
DU at 
baseline at 
20-months 
follow-up.  
Statistical methods applied to assessing the 
relationship between NC and DU healing not 
reported. The method section suggests 
Mann Whitney U used to compare means 
between groups. 
34 pts had DU at baseline. DUs healed in 11/30 vs. 19/30 persisting at 20 
months. Patients whose DU healed had a higher capillary density on 
baseline NC (4.92.3) compared with those with persistent DU (3.31.3, 
p=0.05). NC magnification, number of digits assessed, number of images 
obtained and analysed not reported.  Incomplete description of NC image 
analysis.  Definition of DU healing not reported. Statistical methods 
applied to examining prognostic value of NC not reported. 
Sebastia
ni et al. 
2009 
[31] 
Italy  P L  Develop and 
validate a novel 
NC scoring 
method for 
predicting new 
DU at 3 
months. 
120 pts. 35 
developed 
new DU at 3 
months. 
None 
reported 
1980  ARA 
classification 
criteria for SSc 
Nil 2nd-5th digits 
of both 
hands. 200x 
magn. 
Single image from each 
digit used to quantify 
lowest number of 
capillaries (N), the 
highest number of 
megacapillaries (M) and 
max diameter of  largest 
megacapillary (D). 
Yes  Occurrence 
of new DU 
at 3-month 
follow-up 
ROC curve analysis examined optimal cut-
offs for individual NC parameters (including 
N, M and D) comparing those with/without 
new DU. The composite capillaroscopic skin 
ulcer risk index (CSURI) was devised 
(MxD/N2).  ROC curve analysis used to 
determine optimal CSURI cut-off for 
“predicting” new DU at 3-months.  
ROC curve analysis (comparing patients with new DU at 3 months versus 
those without) revealed an optimal CSURI cut off of 2.94 with PPV of 
73.3%.  No baseline assessment reported to confirm DU at 3 months were 
new rather than refractory.  High rate of new DUs at 3 months (29.2%) 
suggests some might have been present at baseline. Description of model 
building strategy for development of CSURI not reported. ROC curve 
analysis cannot account for potential confounders (such as presence of 
DU at baseline) which might have biased choice of NC image for analysis).  
Hissaria 
et al. 
2011 
[43] 
Australia R L Risk factors for 
mortality in SSc  
NC in 127 
pts (single 
centre) 
from 
registry 786 
pts (1st seen 
1993-2007) 
24 lost to 
follow up 
Modified 1980  
ARA 
classification 
criteria for SSc  
Nil  4th digit of 
both hands. 
16-18x 
magn.  
Cap dilatation and drop-
out categorised as 
normal, mild, moderate 
and severe. NC changes  
scored as (0) normal, (1) 
dilatation, (2) mixed and 
(3) drop out  
Not 
reported 
Mortality  
 
Cox proportional hazards regression Models 
for NC categories were used to evaluate 
relationship between NC and mortality. Not 
clear whether potential confounding effects 
of diffuse cutaneous SSc and ILD adjusted for 
in regression modelling. 
There were 331 deaths (number of deaths in subgroup with NC data not 
reported). No relationship between NC patterns and survival were 
identified (trend for higher mortality with increased capillary drop out). A 
significant Cox Proportional hazards regression ratio of 1.60 (95% CI 1.06-
2.42; P=0.027) was observed when categorical NC patterns were treated 
as continuous variables (scores 0-3) but not clear whether diffuse 
cutaneous SSc and ILD incorporated in hazards model. 
Smith et 
al. 2011 
[36] 
Belgium P L NC predictors 
for future DU at 
6-12 months. 
71 6 subjects 
lost to 
follow-up 
LeRoy and 
Medsger 
classification 
criteria for 
early SSc  [7] 
Nil  2nd-5th digits 
of both 
hands. x200 
magn.  
Mean cap loss at 32 
sites (4/finger) based on 
number of capillaries in 
1mm (0, normal, 1, 
<33% loss [9-12/mm], 2, 
33-66% loss [6-9/mm], 
3, >66% loss [<6/mm]). 
Yes Digital 
trophic 
changes 
using DSS 
peripheral 
vascular 
domain  
ROC curve analysis was undertaken to assess 
optimal cut-offs for mean score of capillary 
loss (calculated at 32 sites, 16 sites, 8 sites 
and at 4 sites) for predicting the presence of 
digital trophic lesions at baseline and at 6-12 
months follow-up. 
Digital trophic changes were present in 19/71 patients at baseline and 
22/65 patients at 6-12 month follow up. The NC image analysis was 
blinded but the choice of images may have been influenced by the 
presence of digital ischaemic lesions at the time of image acquisition. The 
analysis for predicting digital trophic lesions at 6-12 months did not adjust 
for important confounders such as DU at baseline.  Statistical analysis not 
optimal for stated aim of investigating predictive value of NC changes.   
Smith et 
al. 2012 
[37] 
Belgium  P L NC predictors 
of future organ 
complications 
of SSc at 18-24 
months. 
66 8 subjects 
lost to 
follow-up 
LeRoy and 
Medsger 
classification 
criteria for 
early SSc  [7] 
Nil  2nd-5th digits 
of both 
hands at 
x200 magn. 
(x4 1mm 
fields per 
digit) 
Global qualitative 
assessment of 32 NC  
images classified as 
“normal”, “early”, 
“active” and “late” 
changes [5]. 
Yes 9 organs 
systems 
using the 
DSS (0-4 
semi-
quantitative 
score) at 18-
24 months.  
Logistic regression analysis was undertaken, 
converting NVC assessment into a 
continuous variable for most analyses 
(unless rates of organ involvement were 
low).  
Reported significant association between baseline NVC severity (1-4 as 
continuous scale) and presence of severe (category 2-4 of DSS) for 
peripheral vascular and pulmonary (ILD rather than PAH) organ systems 
on 18-24 month assessment. Baseline organ severity not reported and 
not clear whether organ manifestations differed at time of NVC 
assessment and assessment at 18-24 months.  No adjustment for 
confounding effects of disease severity at baseline. Baseline NVC 
associated but not necessarily “predictive” of future organ involvement.   
Sebastia
ni et al. 
2012 
[33] 
Italy P L  Multicentre 
study to 
validate CSURI 
in predicting 
new DU/DU 
healing  at 3 
months. 
242 13 
excluded 
as lack of 
megacapill
aries (a 
feature of 
advanced
disease) 
1980  ARA 
classification 
criteria for SSc 
and at least 1 
megacapillary 
to be able to 
calculate the 
CSURI 
Use of 
bosentan.  
2nd-5th digits 
on both 
hands at 
x200 magn. 
A single image from the 
8 digits used  to 
calculate CSURI score 
was calculated using the 
formula:  DxM/N2 
(as described above 
Sebastiani 2009) 
Not 
reported 
New DU or 
persistence 
of 
old/recurren
ce DU at 3 
months. 
ROC curve analysis examining optimal cut-
off and predictive accuracy for  CSURI when 
comparing patients with new/non-healing 
DU. 
39 patients had DU at baseline (persisted at 3 months in 21 subjects) and 
36 patients developed new DU at 3 months. A CSURI cut-off value of 2.96 
(near identical to earlier study) had a specificity of 81.4% and sensitivity 
of 92.98% for predicting new DU or non-healing of pre-existing ulcers at 3 
months. PPV of CSURI 62.3% with NPV of 97.2%. The analytical approach 
(ROC curve analyses) does not allow for contribution of potentially 
important confounders e.g. disease duration and history of DU. The 
presence of DU at baseline might have influenced NC image acquisition.  
Kayser et 
al. 2013 
[44] 
Brazil R L Risk factors for 
mortality in SSc 
205 70 lost to 
follow-up 
(excluded 
from 
analysis) 
1980 ARA 
classification 
criteria for SSc 
(seen 2001 to 
2009.  
Overlap 
symptom
s to other 
CTD e.g. 
SLE, RA.  
All 10 digits. 
10-25x 
magn.  
 
 
(i) N of cap loops/mm 
(ii) avascular score 
(graded 0-3 according to 
number of avascular 
areas per digit) (iii) N of 
enlarged caps (>4x 
normal size) (iv) N of 
giant NC (>10x normal) 
Yes Mortality 
during mean 
6.5 years of 
follow up. 
Univariate Cox proportional hazards models 
used to examine relationship between 
variables and mortality. A multivariate 
model built using variables identified at 
univariate analysis was created. Survival 
analysis using Kaplan Meier Curve analysis 
was undertaken to analyse survival using an 
arbitrary avascular score cut-off of 1.5. 
There were only 12 deaths (5 of which were attributable to SSc-lung 
involvement) over a variable follow-up ranging from 1-22 years. Three 
patients died secondary to PAH. Univariate analysis identified male 
gender, number of giant capillary loops and avascular score >1.5 as 
associated with increased mortality. After multivariate analysis, only an 
average digital avascular score of >1.5 was associated with a 2-fold 
increased mortality. Important potential confounders e.g. organ 
involvement such as PAH at presentation not accounted in analysis.  
Sebastia
ni et al. 
2013 
[32] 
Italy P L  Multicentre 
study exploring 
predictive value 
of CSURI in 
176 
 
 
 
None 
reported 
1980 ARA 
classification 
criteria for SSc 
Bosentan 
use 
2nd-5th digits 
on both 
hands at 
x200 magn. 
A single image from the 
8 digits was used  to 
calculate CSURI score 
Not 
reported 
New DU or 
persistence 
of 
old/recurren
ROC curve analysis examining optimal cut-
off and predictive accuracy for  CSURI when 
comparing patients with new/non-healing 
DU 
The study examined whether image width (1.33 – 1.70mm) influenced 
predictive value of the CSURI. The optimal CSURI cut-offs (using ROC 
curve analysis) to predict new DU occurrence or non-healing of existing 
DUs differed between cameras (2.13-3.81). The analytical approach did 
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 predicting new 
DU/DU healing. 
(using 3 
different NC 
devices). 
using the formula:  
DxM/N2 
(as described above)) 
t lesions at 3 
months. 
not allow for potentially important confounders e.g. prior history of DU in 
predicting new DU occurrence or non-healing of existing DU. The 
presence of DU at baseline might have influenced NC image acquisition   
Smith et 
al. 2013 
[38] 
Belgium 
& Italy 
P L NC predictors 
of future organ 
complications 
at 18-24 
months 
148 SSc 
patients (66 
Belgium 
patients, 82 
Italian 
patients). 
Insufficien
t follow up 
data on 14 
subjects 
Clinician 
diagnosis of 
SSc. 
Classification 
criterial not 
specified.  
 
Nil 2nd-5th digits 
both hands 
at x200 
magn. (x4 
1mm images 
per digit). 
Global qual assessment 
of 32 NC  images 
classified as  
“nonspecific”, “normal”, 
“early”, “active” and 
“late” changes [5]. 
Yes 9 organ 
systems of 
DSS (0-4 
score) 
and/or new 
PAH/ILD. 
Simple and multiple (adjusting for disease 
duration, disease subset and vasoactive 
medication) logistic regression analysis. 
NC changes at baseline (early, active and late) were associated with a 
significantly increased risk of worsening of the Peripheral Vascular Score 
to >2 points compared with patients with normal/non-specific changes 
(OR 2.96 [95% CI 1.45-7.05], p=0.002 for early versus normal NC pattern) 
on multiple logistic regression analysis. Analysis did not adequately 
control for important potential confounders at baseline assessment.   
Violliot 
et al. 
2015 
[39] 
Belgium 
and Italy 
P L  Predictors of 
(e.g. exercise 
TTE, serum BNP 
and NC) 
associated with 
“CV events” 
during  mean 
follow-up of 27 
± 18 months 
65  15 
excluded 
(unquantif
iable SPAP 
on TTE, 
mitral 
regurgitati
on and/or 
CHD).  
Clinician 
diagnosis of 
SSc.  
Classification 
criterial not 
specified.  
 
Unquantif
iable 
sPAP, 
IHD, 
valvular 
disease, 
unable to 
perform 
exercise 
TTE 
2nd-5th digits 
both hands 
at x200 
magn. 
Global qualitative 
assessment of images 
classified as “normal”, 
“early”, “active” and 
“late” changes [5]. 
Not 
reported 
A 
heterogeneo
us range of 
“CV-events” 
Relationship between  “CV events” 
(comprising  death/hospitalization due to 
left or right heart failure, atrial or ventricular 
arrhythmia, resting PAH confirmed on RHC, 
cerebrovascular attack or peripheral ulcer 
requiring hospitalisation) and NC changes 
(plus serum BNP, demographics, resting and 
exercise TTE data) evaluated using simple 
linear regression. Independent predictors of 
CV events assessed using multiple logistic 
regression analyses.  
Heterogeneous mix of CV events in 9/50 patients. Patients with “CV 
events” were older, higher baseline BNP levels and differences in baseline 
TTE parameters e.g. higher baseline sPAP, higher exercise sPAP and larger 
LA area. Patients with future CV events were more likely to have late NC 
changes and less likely to have early NC changes. The relationship 
between an NC “active”/”late” changes and future CV events persisted 
after adjustment for age and sex.  Multiple logistic regression analysis 
adjusted for age and gender but did not adjust for other important 
potential confounders (e.g. BNP, exercise TTE parameters etc.) which had 
an incremental effect on future CV events.  There was  limited description 
of baseline features, recruitment period, length of follow-up, blinding etc.  
Silva et 
al. 2015 
[34] 
Portugal 
 
 
P L Risk factors 
(including NC) 
for further DU 
recurrence in 
patients with 
history of DU 
(group 1) or 1st 
DU (group 2) 
over  3 years 
77  
(group 1  
n=38 and 
group 2 
n=39) 
 
Nil  2013 
ACR/EULAR 
classification 
criteria 
Smokers, 
diabetes, 
hyperlipid
aemia, 
history of 
MI and 
bosentan 
use 
200x magn. 
Number of 
digits 
assessed 
and images 
obtained/as
sessed not 
supplied. 
Global qualitative 
assessment of images 
classified as “normal”, 
“early”, “active” and 
“late” changes [5]. 
Not 
reported 
DU 
reoccurrenc
e (group 1) 
or 1st DU 
event (group 
2) in the 3 
year follow 
up period 
Univariate and multivariate cox regression 
analyses used to evaluate association 
between baseline variables (including NC 
pattern) and DU reoccurrence (Group 1) or 
1st DU event (Group 2). 
30/38 (79%) of patients in group 1 had DU reoccurrence within 3 years. 
Univariate and multivariate analyses both identified NVC “late” pattern as 
a predictor of DU reoccurrence in group 1 patients (HR 2.49 [95%CI 1.03-
6.04] on multivariate cox regression analysis). 10/39 patients in group 2 
experienced their first DU in 3-year clinical follow up.  Univariate and 
multivariate analyses both identified NVC “late” pattern as a predictor of 
1st DU occurrence in group 2 patients (HR 13.38, [95%CI 2.10-85.38] on 
multivariate cox regression analysis). Limited description of NC methods 
and image analysis. Inadequate adjustment for confounders.  
Manfredi 
et al. 
2015 
[30] 
Italy P L Multicentre 
study 
examining risk 
factors for new 
DU over 6 
months  
219  Nil 2013 
ACR/EULAR 
classification 
criteria 
Use of 
Bosentan 
2nd-5th digits 
of both 
hands. 200x 
magn. 1 
image/finger 
obtained. 
A single image from the 
8 digits used  to 
calculate CSURI using 
the formula:  DxM/N2 
(as described above 
Sebastiani 2009) 
Not 
reported  
The 
occurrence 
of new DU 
over 6-
month 
follow-up 
Univariate and multivariate analysis to 
examine predictive value of baseline NVC 
changes at predicting new DU in 6 months of 
follow up. A prediction chart was devised 
using parameters identified in multivariate 
logistic regression analysis. 
Multivariate analysis identified the CSURI cut off of 2.96 as highly 
predictive for new DU at 6 months.  Approximately 84 pts had recent 
history/active DU at baseline and a similar number had a CSURI of >2.96 
suggesting possible overlap. The high odds ratio (99.95 (95%CI 20.03-
498.86, P<0.001) at multivariate analysis suggests quasi-complete 
separation owing to strong relationship between CSURI and baseline DU.  
Violliot 
et al. 
2016 
[40] 
 
 
 
Belgium 
and Italy 
P L  Risk factors 
(resting TTE 
parameters, 
BNP, NC, PFTs) 
for PAH  or 
EIPH 25 15 
months follow-
up 
68 recruited 
(2008- 
2012). 40 
included in 
analysis.   
 
 
5 refused 
to take 
part. 
2 lost to 
follow-up.  
21 
excluded. 
Clinician 
diagnosis of SSc 
CHD, 
valve 
disease, 
PAH, no 
exercise 
test or no 
TR on TTE 
2nd-5th digits 
both hands 
at x200 
magn.  
Global qualitative 
assessment of images 
classified as 0, 
“normal”; 1, “early”; 2, 
“active” and 3, “late” 
changes [5]. 
Not 
reported 
PAH defined 
as estimated 
TTE sPAP 
>35mmHg. 
EIPH as 
estimated 
TTE sPAP 
>50mmHg 
Univariate and multivariable logistic 
regression and cox proportional hazards 
models were performed to define predictors 
of new onset PAH. 
 
 
 
EIPH occurred in 11 patients (28%) during follow up. Patients developing 
EIPH had higher levels of baseline BNP, sPAP, mPAP and sPAP on TTE. 
After adjusting for age, patients with NVC>2 (“active”/”late”) were more 
likely to develop PAH during follow up (hazard ratio 9.1, 95% CI 1.1-74.8; 
P=0.04).   Multivariate analysis of more than 2 variables was not possible 
(small study size and low event rate) raising concerns regarding type II 
error. The exclusion criteria and reliance on TTE parameters may also 
reduce the generalisability of findings across unselected SSc cohorts. 
Baron et 
al. 2016 
[41] 
Canada 
and 
Mexico 
R L  Multicentre 
longitudinal 
study 
examining risk 
factors for 
calcinosis  
1305 
patients 
recruited at 
15 sites 
(2004 to 
2015) 
500 pts 
excluded 
from 
analysis 
Clinician 
diagnosis of SSc 
antibody data 
and calcinosis 
assessment at 
baseline 
Baseline 
calcinosis 
(n=300) 
or no 
follow-up 
(n=200) 
Dermatosco
pe used for 
NC. Details 
not 
reported. 
Physician recorded the 
presence of capillary 
drop-out areas. 
Not 
reported  
Developmen
t of 
calcinosis 
during mean 
follow up of 
3.8years 
Univariate and multivariate analysis 
examined predictors of calcinosis. A cox 
proportional hazards model examined the 
association between baseline markers of 
tissue ischaemia (including capillary drop 
out) and future development of calcinosis. 
Capillary dropout at baseline was considered a significant univariate 
predictor of calcinosis during follow-up (p=0.063). In a sensitivity analysis, 
capillary drop out at baseline was also associated with the development 
of calcinosis (HR 1.46, 95% CI: 1.08, 1.99). Limited details were provided 
regarding the NC image acquisition and analysis.  
Cutolo et 
al. 2016 
[29] 
 
 
 
59 SSc 
centres 
across 14 
countries 
(12 in 
Europe, 
Turkey 
and 
Israel) 
P L Multicentre 
study 
examining risk 
factors 
(particularly 
NC) for new DU 
occurrence 
over 6 months  
623 
patients: 
468 in 
group 1  
and 123 in 
group 2)  
 
 
 
No 
evaluable 
DU 
outcome 
data for 
32 
patients.  
 
 
 
 
Classification 
criteria for 
early SSc  [7]  
1. history of DU 
or DU at 
enrolment 
(group 1) 
2. Disease 
duration of <2 
years (group 2) 
Inability 
to do NC, 
SSc sine 
scleroder
ma, 
previous 
HSCT or 
clinical 
trial 
within 3 
months  
2nd-5th digits 
both hands 
at x200 
magn. 
capturing 2 
adjacent 
fields 
extending 
over 1mm at 
the midline. 
Qualitative assessment 
classified as “normal”, 
“early”, “active” and 
“late” changes [5]. 
Quant assessment of n 
of caps, giant caps, 
irregularly enlarged 
caps, micro-
haemorrhages and 
neoangiogenesis. 
Maximal cap diameter  
was measured. 
No Occurrence 
of new DU 
reported 
during 
monthly 
monitoring 
phone calls 
to patients 
(confirmed 
at study 
visit). 
Stratified analysis undertaken focussing on 
patients with history of DU (n=468). Logistic 
regression modelling (including linear and 
quadratic functional relationships) examined 
discriminatory ability of co-variables for the 
occurrence of new DU. Strength of 
association reported using odds ratio and 
discriminatory performance assessed using 
ROC AUC analyses. Multiple logistic 
regression modelling used to identify best-
performing clinical and NC risk factors for 
DU occurrence. 
There were 103 new DU in group 1 patients and only 5 new DU in the 
group 2 patients. The presence and number of DU present at baseline 
was the strongest predictor of new DU during follow up.  
Qualitative NC pattern was associated with new DU occurrence when 
comparing “late” versus “normal/early”. The mean number of capillaries 
was significant lower in patients who experienced new DU compared with 
those who did not. The final multiple logistic regression identified 3 risk 
factors for DU occurrence that included: 1) Mean number of 
capillaries/mm in middle finger of dominant hand, 2) the number of DUs 
at enrolment visit and 3) the presence of critical digital ischaemia at 
enrolment.  The stratified analysis reduces the generalisability of the 
findings in patients without a history of DU. 
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ACR, American College of Rheumatology; AF, atrial fibrillation; AUC, area under curve; ARA, Australian Rheumatology Association; BNP, Brain Natriuretic Peptide; Cap, capillary; CHD, Coronary 
Heart Disease; CI, Confidence Intervals; CSURI, capillaroscopic skin ulcers risk index; CV, Cardiovascular; DU, Digital Ulcers; DSS, Disease Severity Score; EULAR, European League Against 
Rheumatism; EIPH, Exercise-induced Pulmonary Hypertension; FVC, Forced Vital Capacity; IHD, Ischaemic Heart Disease; ILD, Interstitial Lung Disease; Hb, Haemoglobin; HDL, High-density 
Lipoprotein; HRCT, High Resolution Computed Tomography; HR, Hazards Ratio; HSCT, Haematopoietic Stem Cell Transplantation; LA, Left Atrium; LVEF, Left Ventricular Ejection Fraction; MI, 
Myocardial Infarction; mPAP, mean Pulmonary Arterial Pressure; NC, Nailfold Capillaroscopy; NPV, Negative Predictive Value; OR, Odds Ratio; P, Prospective; Pts, patients; PAH, Pulmonary 
Arterial Hypertension; PF, Pulmonary Fibrosis; PPV, Positive Predictive Value; Qual, qualitative; Quant, quantitative; R, Retrospective; RA, Rheumatoid Arthritis; RHC, Right Heart Catheterisation; 
ROC, Receiver Operating Characteristic; RSS, Rodnan Skin Score; SLE, Systemic Lupus Erythematosus; sPAP, systolic Pulmonary Arterial Pressure; SSc, Systemic Sclerosis; TIA, Transient Ischaemic 
Attack; TTE, Transthoracic Echocardiogram; vTR, velocity Tricuspid Regurgitation. 
Avouac 
et al. 
2017 
[28] 
France, 
Italy, 
Belgium 
P L Study 
examining 
evolution of NC 
changes and 
relationship 
with disease 
progression 
over 3 year 
follow-up. 
 
 
 
146 
Enrolled 
(2011 to 
2012). 
 
6 patients 
died 
during 
follow up. 
15 
patients 
lost to 
follow-up. 
2013 
ACR/EULAR 
classification 
criteria 
Nil   2nd-5th digits 
both hands 
at x200 
magn. Two 
consecutive 
fields 
extending 
over 1mm at 
midline. NC 
repeated 
annually for 
3 years. 
Quantitative 
assessment of the mean 
number of a) capillaries 
per mm, b) giant 
capillaries per mm, c) 
microhaemorrhages per 
mm and d) 
neoangiogenesis per 
mm. A qualitative 
grading of NVC changes 
as “early”, “active” and 
“late” NVC patterns.[5]  
Yes “Disease 
progression” 
during 3 
year follow- 
up.  
“Disease progression” defined as 
progression of modified RSS (≥30% and ≥5 
point increase), occurrence of DU, new 
onset PAH on RHC, cardiac involvement 
(LVEF to <50% on TTE), renal crisis, 
progression of ILD (new onset ILD on HRCT 
or >10% fall in FVC) or worsening of the DSS 
(from category 1-2 to 3-4 for any organ 
system). An analysis of the predictive value 
of baseline NC changes using univariate Cox 
proportional hazards models followed by 
multivariate analysis including all variables 
with P<0.1 from univariate analysis. 
Baseline capillary loss was predictor of overall disease progression, 
occurrence of new DU, lung vascular progression, skin progression and 
worsening of the DSS at univariate analysis but not multivariate analysis. 
In contrast, neoangiogenesis at baseline retained a significant association 
with the lung vascular progression (HR 11.12, 95%CI 1.19-103.79, 
p=0.036) on multivariate analysis adjusting for confounders. Evolution of 
NC abnormalities was more important; progression in the number of 
giant caps was protective for occurrence of new DU and overall disease 
progression. Progression of cap loss was independently associated with 
overall disease progression, occurrence of new DU, lung vascular 
progression, skin progression and worsening of the DSS. Progression to 
“late” NVC changes independently associated with new DU, development 
of PAH, progression of skin fibrosis and worsening of the DSS.  
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Table 2. Risk of bias assessment in studies reporting the prognostic value of nailfold 
capillaroscopy in systemic sclerosis using the QUality in Prognosis Studies (QUIPS) tool.   
Author & Year of 
Publication 
Study 
Participation 
Study 
Attrition 
Prognostic 
Factor 
Measurement 
Outcome 
Measurement 
Study 
Confounding 
Statistical 
Analysis & 
Reporting 
Scussel-Lonzetti et al. 
2002 [42] 
Low Low Low Low High High 
Simeón et al. 2003 [35] Low Low Moderate  Low Moderate Moderate 
Alivernini et al. 2009 
[27] 
Low Low High Moderate Low High 
Sebastiani et al. 2009 
[31]  
Moderate  Low Moderate Moderate  High   High 
Hissaria et al. 2011 [43] Low Low Low Low High Moderate 
Smith et al. 2011 [36] Low Low Low Low High High 
Smith et al. 2012 [37] Low Low Low Low High Moderate 
Sebastiani et al. 2012 
[33] 
Low Low Moderate Moderate High High 
Kayser et al. 2013 [44] Low High Low Low High Low 
Sebastiani et al. 2013 
[32] 
Low Low Moderate Moderate High High 
Smith et al. 2013 [38] Moderate Moderate Low Low Low Moderate 
Violliot et al. 2015 [39] Moderate Low Moderate  Low High  Moderate 
Silva et al. 2015 [34] Low Low Moderate  Low Moderate Low 
Manfredi et al. 2015[30] Moderate Low Moderate Low High  Moderate 
Violliot et al. 2016 [40] Moderate  Moderate Moderate Low High Moderate 
Baron et al. 2016 [41] Low Low Moderate  Low Low Low 
Cutolo et al. 2016 [29]  Moderate Low Low Moderate Low Low 
Avouac et al. 2017 [28] Low Low Low Low Low Low 
Totals: 
Low (58) 
Mod (31) 
High (19) 
 
12 
6 
0 
 
15 
2 
1 
 
8 
9 
1 
 
13 
5 
0 
 
5 
2 
11 
 
5 
7 
6 
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The prognostic value of nailfold capillaroscopic abnormalities in systemic sclerosis: A 
systematic literature review 
Dolcie Paxton BSc & John D Pauling BMedSci BMBS PhD FRCP  
 
 
Supplementary Material 1. Details of full search criteria applied in MEDLINE and EMBASE 
databases for study identification. 
 
 
MEDLINE search 
 
(Nailfold videocapillaroscopy or nailfold capillary microscopy or capillaroscopy or 
microscopic angioscopy) AND (scleroderma, systemic or scleroderma or systemic 
scleroderma or systemic sclerosis or CREST) AND (cohort studies or Longitudinal studies or 
case-control studies or follow-up studies or retrospective studies or cross-sectional studies 
or prospective studies or incidence or mortality or follow-up studies or prognos*or predict* 
or course or prognostic or prognosis or progression or future or development or treatment 
outcome or disease-free survival or treatment failure or morbidity or prevalence or survival 
rate or cause of death or survival analysis) 
 
The expanded search is detailed below: 
  
((nailfold[All Fields] AND ("microscopic angioscopy"[MeSH Terms] OR ("microscopic"[All 
Fields] AND "angioscopy"[All Fields]) OR "microscopic angioscopy"[All Fields] OR 
"videocapillaroscopy"[All Fields])) OR (nailfold[All Fields] AND ("capillaries"[MeSH Terms] OR 
"capillaries"[All Fields] OR "capillary"[All Fields]) AND ("microscopy"[MeSH Terms] OR 
"microscopy"[All Fields])) OR ("microscopic angioscopy"[MeSH Terms] OR ("microscopic"[All 
Fields] AND "angioscopy"[All Fields]) OR "microscopic angioscopy"[All Fields] OR 
"capillaroscopy"[All Fields]) OR ("microscopic angioscopy"[MeSH Terms] OR 
("microscopic"[All Fields] AND "angioscopy"[All Fields]) OR "microscopic angioscopy"[All 
Fields])) AND (("scleroderma, systemic"[MeSH Terms] OR ("scleroderma"[All Fields] AND 
"systemic"[All Fields]) OR "systemic scleroderma"[All Fields] OR ("scleroderma"[All Fields] 
AND "systemic"[All Fields]) OR "scleroderma, systemic"[All Fields]) OR ("scleroderma, 
systemic"[MeSH Terms] OR ("scleroderma"[All Fields] AND "systemic"[All Fields]) OR 
"systemic scleroderma"[All Fields] OR "scleroderma"[All Fields] OR "scleroderma, 
localized"[MeSH Terms] OR ("scleroderma"[All Fields] AND "localized"[All Fields]) OR 
"localized scleroderma"[All Fields]) OR ("scleroderma, systemic"[MeSH Terms] OR 
("scleroderma"[All Fields] AND "systemic"[All Fields]) OR "systemic scleroderma"[All Fields] 
OR ("systemic"[All Fields] AND "scleroderma"[All Fields])) OR ("scleroderma, 
systemic"[MeSH Terms] OR ("scleroderma"[All Fields] AND "systemic"[All Fields]) OR 
"systemic scleroderma"[All Fields] OR ("systemic"[All Fields] AND "sclerosis"[All Fields]) OR 
"systemic sclerosis"[All Fields]) OR ("crest syndrome"[MeSH Terms] OR ("crest"[All Fields] 
AND "syndrome"[All Fields]) OR "crest syndrome"[All Fields] OR "crest"[All Fields])) AND 
(("cohort studies"[MeSH Terms] OR ("cohort"[All Fields] AND "studies"[All Fields]) OR 
"cohort studies"[All Fields]) OR ("longitudinal studies"[MeSH Terms] OR ("longitudinal"[All 
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Fields] AND "studies"[All Fields]) OR "longitudinal studies"[All Fields]) OR ("case-control 
studies"[MeSH Terms] OR ("case-control"[All Fields] AND "studies"[All Fields]) OR "case-
control studies"[All Fields] OR ("case"[All Fields] AND "control"[All Fields] AND "studies"[All 
Fields]) OR "case control studies"[All Fields]) OR ("follow-up studies"[MeSH Terms] OR 
("follow-up"[All Fields] AND "studies"[All Fields]) OR "follow-up studies"[All Fields] OR 
("follow"[All Fields] AND "up"[All Fields] AND "studies"[All Fields]) OR "follow up studies"[All 
Fields]) OR ("retrospective studies"[MeSH Terms] OR ("retrospective"[All Fields] AND 
"studies"[All Fields]) OR "retrospective studies"[All Fields]) OR ("cross-sectional 
studies"[MeSH Terms] OR ("cross-sectional"[All Fields] AND "studies"[All Fields]) OR "cross-
sectional studies"[All Fields] OR ("cross"[All Fields] AND "sectional"[All Fields] AND 
"studies"[All Fields]) OR "cross sectional studies"[All Fields]) OR ("prospective 
studies"[MeSH Terms] OR ("prospective"[All Fields] AND "studies"[All Fields]) OR 
"prospective studies"[All Fields]) OR ("epidemiology"[Subheading] OR "epidemiology"[All 
Fields] OR "incidence"[All Fields] OR "incidence"[MeSH Terms]) OR ("mortality"[Subheading] 
OR "mortality"[All Fields] OR "mortality"[MeSH Terms]) OR ("follow-up studies"[MeSH 
Terms] OR ("follow-up"[All Fields] AND "studies"[All Fields]) OR "follow-up studies"[All 
Fields] OR ("follow"[All Fields] AND "up"[All Fields] AND "studies"[All Fields]) OR "follow up 
studies"[All Fields]) OR ((prognose[All Fields] AND *or[All Fields]) AND (predict[All Fields] OR 
predict'[All Fields] OR predict''[All Fields] OR predict's[All Fields] OR predict7[All Fields] OR 
predicta[All Fields] OR predictab[All Fields] OR predictabe[All Fields] OR predictabel[All 
Fields] OR predictabilities[All Fields] OR predictability[All Fields] OR predictability'[All Fields] 
OR predictability''[All Fields] OR predictabilty[All Fields] OR predictable[All Fields] OR 
predictable'[All Fields] OR predictables[All Fields] OR predictablility[All Fields] OR 
predictablity[All Fields] OR predictably[All Fields] OR predictabuity[All Fields] OR 
predictad[All Fields] OR predictal[All Fields] OR predictalbe[All Fields] OR predictand[All 
Fields] OR predictands[All Fields] OR predictaquatic[All Fields] OR predictar[All Fields] OR 
predictate[All Fields] OR predictated[All Fields] OR predictative[All Fields] OR predictbias[All 
Fields] OR predictcancer[All Fields] OR predictcing[All Fields] OR predictd[All Fields] OR 
predictdr[All Fields] OR predicte[All Fields] OR predicted[All Fields] OR predicted'[All Fields] 
OR predictedfev[All Fields] OR predictedfrom[All Fields] OR predictedindices[All Fields] OR 
predictedinteractions[All Fields] OR predictedl[All Fields] OR predictedly[All Fields] OR 
predictedmore[All Fields] OR predictedness[All Fields] OR predictedproperties[All Fields] OR 
predicteds[All Fields] OR predictedx100[All Fields] OR predictee[All Fields] OR predictees[All 
Fields] OR predictek[All Fields] OR predicter[All Fields] OR predicters[All Fields] OR 
predictet[All Fields] OR predicteur[All Fields] OR predicteurs[All Fields] OR predictfold[All 
Fields] OR predictfurors[All Fields] OR predicthaplo[All Fields] OR predicther[All Fields] OR 
predicthospital[All Fields] OR predicti[All Fields] OR predictia[All Fields] OR predictiable[All 
Fields] OR predictibilidad[All Fields] OR predictibilitate[All Fields] OR predictibilite[All Fields] 
OR predictibility[All Fields] OR predictible[All Fields] OR predictically[All Fields] OR 
predictice[All Fields] OR predictictive[All Fields] OR predicticvity[All Fields] OR predictie[All 
Fields] OR predictied[All Fields] OR predictief[All Fields] OR predictieformules[All Fields] OR 
predictiemodel[All Fields] OR predictiemodellen[All Fields] OR predictieregels[All Fields] OR 
predicties[All Fields] OR predictieve[All Fields] OR predictif[All Fields] OR predictif's[All 
Fields] OR predictifs[All Fields] OR predictim[All Fields] OR predictin[All Fields] OR 
predictinf[All Fields] OR predicting[All Fields] OR predicting'[All Fields] OR predicting14[All 
Fields] OR predictingdti[All Fields] OR predictinginteractions[All Fields] OR 
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predictingprognosis[All Fields] OR predictingthe[All Fields] OR predictintegral[All Fields] OR 
predictio[All Fields] OR predictiom[All Fields] OR prediction[All Fields] OR prediction'[All 
Fields] OR prediction's[All Fields] OR prediction36[All Fields] OR predictionable[All Fields] OR 
predictional[All Fields] OR predictionalgorithms[All Fields] OR predictioncenter[All Fields] OR 
predictioncomputations[All Fields] OR predictionequations[All Fields] OR predictiong[All 
Fields] OR predictioning[All Fields] OR predictionnel[All Fields] OR predictionof[All Fields] OR 
predictions[All Fields] OR predictions'[All Fields] OR predictionst[All Fields] OR 
predictionswere[All Fields] OR predictior[All Fields] OR predictis[All Fields] OR predictit[All 
Fields] OR predictition[All Fields] OR predictitive[All Fields] OR predictits[All Fields] OR 
predictiv[All Fields] OR predictiva[All Fields] OR predictivas[All Fields] OR predictive[All 
Fields] OR predictive'[All Fields] OR predictiveanalytics[All Fields] OR predictiveathletes[All 
Fields] OR predictiveathletes'[All Fields] OR predictivebio[All Fields] OR predictivefactor[All 
Fields] OR predictivefactors[All Fields] OR predictivefactorsfor[All Fields] OR 
predictivehealth[All Fields] OR predictivein[All Fields] OR predictively[All Fields] OR 
predictively'[All Fields] OR predictivemodel[All Fields] OR predictiveness[All Fields] OR 
predictiveness'[All Fields] OR predictivenets[All Fields] OR predictivenetworks[All Fields] OR 
predictiveof[All Fields] OR predictives[All Fields] OR predictivesolutions[All Fields] OR 
predictivetrade[All Fields] OR predictivevalue[All Fields] OR predictivevalues[All Fields] OR 
predictivi[All Fields] OR predictivie[All Fields] OR predictivism[All Fields] OR predictivist[All 
Fields] OR predictivite[All Fields] OR predictivites[All Fields] OR predictivities[All Fields] OR 
predictivity[All Fields] OR predictivo[All Fields] OR predictivos[All Fields] OR predictivre[All 
Fields] OR predictivy[All Fields] OR predictly[All Fields] OR predictlymph[All Fields] OR 
predictmalaga[All Fields] OR predictmdxtrade[All Fields] OR predictment[All Fields] OR 
predictnls[All Fields] OR predictol[All Fields] OR predictome[All Fields] OR predictomics[All 
Fields] OR predicton[All Fields] OR predictons[All Fields] OR predictor[All Fields] OR 
predictor'[All Fields] OR predictor''[All Fields] OR predictor's[All Fields] OR predictor2[All 
Fields] OR predictora[All Fields] OR predictoras[All Fields] OR predictore[All Fields] OR 
predictoren[All Fields] OR predictores[All Fields] OR predictoresde[All Fields] OR 
predictorfor[All Fields] OR predictorganic[All Fields] OR predictormultiple[All Fields] OR 
predictorof[All Fields] OR predictorr[All Fields] OR predictors[All Fields] OR predictors'[All 
Fields] OR predictors'of[All Fields] OR predictors,[All Fields] OR predictors1[All Fields] OR 
predictorsand[All Fields] OR predictorsof[All Fields] OR predictorsqbetween[All Fields] OR 
predictorstate[All Fields] OR predictortrade[All Fields] OR predictorvsl2[All Fields] OR 
predictorxgroup[All Fields] OR predictory[All Fields] OR predictove[All Fields] OR 
predictovos[All Fields] OR predictox[All Fields] OR predictpatientevents[All Fields] OR 
predictprotei[All Fields] OR predictprotein[All Fields] OR predictprotein'[All Fields] OR 
predictree[All Fields] OR predictregulon[All Fields] OR predictreturn[All Fields] OR 
predictrive[All Fields] OR predicts[All Fields] OR predictsa[All Fields] OR predictsgrna[All 
Fields] OR predictsnon[All Fields] OR predictsnp[All Fields] OR predictsnp1[All Fields] OR 
predictsnp2[All Fields] OR predictt[All Fields] OR predicttga[All Fields] OR predictthe[All 
Fields] OR predicttion[All Fields] OR predicttive[All Fields] OR predicttoxicity[All Fields] OR 
predicttrade[All Fields] OR predictve[All Fields] OR predictyate[All Fields])) OR course[All 
Fields] OR prognostic[All Fields] OR ("prognosis"[MeSH Terms] OR "prognosis"[All Fields]) 
OR ("disease progression"[MeSH Terms] OR ("disease"[All Fields] AND "progression"[All 
Fields]) OR "disease progression"[All Fields] OR "progression"[All Fields]) OR 
("forecasting"[MeSH Terms] OR "forecasting"[All Fields] OR "future"[All Fields]) OR ("growth 
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and development"[Subheading] OR ("growth"[All Fields] AND "development"[All Fields]) OR 
"growth and development"[All Fields] OR "development"[All Fields]) OR ("treatment 
outcome"[MeSH Terms] OR ("treatment"[All Fields] AND "outcome"[All Fields]) OR 
"treatment outcome"[All Fields]) OR ("disease-free survival"[MeSH Terms] OR ("disease-
free"[All Fields] AND "survival"[All Fields]) OR "disease-free survival"[All Fields] OR 
("disease"[All Fields] AND "free"[All Fields] AND "survival"[All Fields]) OR "disease free 
survival"[All Fields]) OR ("treatment failure"[MeSH Terms] OR ("treatment"[All Fields] AND 
"failure"[All Fields]) OR "treatment failure"[All Fields]) OR ("epidemiology"[Subheading] OR 
"epidemiology"[All Fields] OR "morbidity"[All Fields] OR "morbidity"[MeSH Terms]) OR 
("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR 
"prevalence"[MeSH Terms]) OR ("survival rate"[MeSH Terms] OR ("survival"[All Fields] AND 
"rate"[All Fields]) OR "survival rate"[All Fields]) OR ("cause of death"[MeSH Terms] OR 
("cause"[All Fields] AND "death"[All Fields]) OR "cause of death"[All Fields]) OR ("survival 
analysis"[MeSH Terms] OR ("survival"[All Fields] AND "analysis"[All Fields]) OR "survival 
analysis"[All Fields])) 
 
 
EMBASE search 
 
Nailfold videocapillaroscopy or nailfold capillary microscopy or capillaroscopy or 
microscopic angioscopy 
  
AND 
  
scleroderma, systemic or scleroderma or systemic scleroderma or systemic sclerosis or 
CREST 
  
AND 
  
cohort studies or Longitudinal studies or case-control studies or follow-up studies or 
retrospective studies or cross-sectional studies or prospective studies or incidence or 
mortality or follow-up studies or prognos*or predict* or course or prognostic or prognosis 
or progression or future or development or treatment outcome or disease-free survival or 
treatment failure or morbidity or prevalence or survival rate or cause of death or survival 
analysis
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Supplementary Materials 2. The “QUality In Prognosis Studies” (QUIPS) risk-of-bias tool. 
The following criteria were used to rate the risk of bias across the 6 domains of the QUIPS tool. Adapted from [25]. PF, prognostic factor. 
 
Bias Domain Optimal Study 
Description 
Prompting Items and Considerations Final rating 
Study 
Participation 
The study sample 
adequately 
represents the 
population of 
interest 
a. Adequate participation in the study by eligible persons 
b. Description of the source population or population of interest 
c. Description of the baseline study sample 
d. Adequate description of the sampling frame and recruitment 
e. Adequate description of the period and place of recruitment 
f. Adequate description of inclusion and exclusion criteria 
High bias: The relationship between the PF and outcome is very likely 
to be different for participants and eligible nonparticipants 
Moderate bias: The relationship between the PF and outcome may be 
different for participants and eligible nonparticipants 
Low bias: The relationship between the PF and outcome is unlikely to 
be different for participants and eligible nonparticipants 
Study Attrition The study data 
available (i.e., 
participants not lost 
to follow-up) 
adequately 
represent the study 
sample 
a. Adequate response rate for study participants 
b. Description of attempts to collect information on participants who dropped out 
c. Reasons for loss to follow-up are provided 
d. Adequate description of participants lost to follow-up 
e. There are no important differences between participants who completed the study and those 
who did not 
High bias: The relationship between the PF and outcome is very likely 
to be different for completing and non-completing participants 
Moderate bias: The relationship between the PF and outcome may be 
different for completing and non-completing participants 
Low bias: The relationship between the PF and outcome is unlikely to 
be different for completing and non-completing participants 
Prognostic 
Factor (PF) 
Measurement  
The prognostic 
factor is measured 
in a similar way for 
all participants 
a. A clear definition or description of the PF is provided 
b. Method of PF measurement is adequately valid and reliable 
c. Continuous variables are reported or appropriate cut points are used 
d. The method and setting of measurement of PF is the same for all study participants 
e. Adequate proportion of the study sample has complete data for the PF 
f. Appropriate methods of imputation are used for missing PF data 
High bias: The measurement of the PF is very likely to be different for 
different levels of the outcome of interest 
Moderate bias: The measurement of the PF may be different for 
different levels of the outcome of interest 
Low bias: The measurement of the PF is unlikely to be different for 
different levels of the outcome of interest 
Outcome 
Measurement  
The outcome of 
interest is 
measured in a 
similar way for all 
participants 
a. A clear definition of the outcome is provided 
b. Method of outcome measurement used is adequately valid and reliable 
c. The method and setting of outcome measurement is the same for all study participants 
High bias: The measurement of the outcome is very likely to be 
different related to the baseline level of the PF 
Moderate bias: The measurement of the outcome may be different 
related to the baseline level of the PF 
Low bias: The measurement of the outcome is unlikely to be different 
related to the baseline level of the PF 
Study 
Confounding 
Important potential 
confounding factors 
are appropriately 
accounted for 
a. All important confounders are measured 
b. Clear definitions of the important confounders measured are provided 
c. Measurement of all important confounders is adequately valid and reliable 
d. The method and setting of confounding measurement are the same for all study participants 
e. Appropriate methods are used if imputation is used for missing confounder data 
f. Important potential confounders are accounted for in the study design 
g. Important potential confounders are accounted for in the analysis 
High bias: The observed effect of the PF on the outcome is very likely 
to be distorted by another factor related to PF and outcome 
Moderate bias: The observed effect of the PF on outcome may be 
distorted by another factor related to PF and outcome 
Low bias: The observed effect of the PF on outcome is unlikely to be 
distorted by another factor related to PF and outcome 
Statistical 
Analysis and 
Reporting 
The statistical 
analysis is 
appropriate, and all 
primary outcomes 
are reported 
a. Sufficient presentation of data to assess the adequacy of the analytic strategy 
b. Strategy for model building is appropriate and is based on a conceptual framework or model 
c. The selected statistical model is adequate for the design of the study 
d. There is no selective reporting of results 
High bias: The reported results are very likely to be spurious or biased 
related to analysis or reporting 
Moderate bias: The reported results may be spurious or biased related 
to analysis or reporting 
Low bias: The reported results are unlikely to be spurious or biased 
related to analysis or reporting 
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Supplementary Materials 3. Details of inter-reviewer agreement during initial title and abstract 
review for eligible articles.  
 
Details of agreement between reviewers for the title and abstract review 
 
 DP include DP Exclude Total 
JP Include 18 7 25 
JP Exclude 8 686 694 
Total 26 693 719 
 
Number of observed agreements: 704 (97.91%) 
 
Kappa = 0.6951 (95% CI 0.549-0.841) 
SE of kappa=0.075 
 
Of the 15 citations for which there was disagreement: 
 
5 papers were included in full text analysis (2 which JP had initially considered including) 
10 papers were excluded (5 which JP had initially considered including) 
 
This resulted in a total of 23 papers proceeding to full text review.  
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Supplementary Material 4. Details of inter-reviewer agreement during QUIPS risk-of-bias assessment 
of articles taken forward to full data extraction 
 
Details of agreement between reviewers for the QUIPS assessment 
 
  DP assessment Totals 
JP 
asssessment 
 Low Mod High  
Low 44 8 1 53 
Mod 17 18 4 39 
High 3 1 11 15 
Totals  64 27 16 107* 
 
* DP was undecided on 1 assessment and did not disclose an opinion during independent QUIPS 
assessment. 
  
Number of observed agreements: 73 ( 68.22% of the observations)  
Number of agreements expected by chance: 43.8 ( 40.92% of the observations) 
 
Kappa= 0.462  
SE of kappa = 0.075  
95% confidence interval: From 0.314 to 0.610  
The strength of agreement is considered to be 'moderate'. 
 
The calculations above only consider exact matches between observers. As the categories (Low, Mod 
and High) are ordered, we also considered close matches. In other words, if one observer classifies a 
bias assessment as Moderate and the other rater High, this is closer than if one classifies one as Low 
and the other rater as High. The calculation of weighted kappa, below, assumes the categories are 
ordered and accounts for how far apart the two raters are. This calculation uses linear weights. 
 
Weighted Kappa= 0.526 
 
Assessed this way, the strength of agreement is considered to be 'moderate'. 
 
A meeting was held between JP and DP on the 14th September to discuss dispcrepancies in agreement. 
The following decisions were agreed: 
 
 For the manuscript that DP could not apply a grading, consensus was reached to apply JP 
grading 
 For 5 gradings, it was agreed that we would apply the initial grading provided by DP 
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 For 28 gradings, it was agreed that we would apply the initial grading provided by JP 
 For 1 grading, where there had been disagreement, we applied an entirely new grading (High 
when we had initially graded Moderate and Low respectively) 
 For 3 gradings, where there had initially been agreement (both reviewers rated moderate), we 
applied a new grading (increased to high) based on further review of the study alongside 
similar assessments made for other studies. 
 
